Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry

Jeffrey R. Curtis; Aseem Bharat; Lang Chen; Jeffrey D. Greenberg; Leslie Harrold; Joel M. Kremer; Tanya Sommers; Dimitrios Pappas

doi:10.3899/jrheum.151136

Article Figures & Data

Tables

View popup

Table 1.

Factors associated with patients with RA missing some or all MTX doses in the last 4 weeks whose rheumatologist reported MTX use at the most recent registry visit (n = 228 patients). Values are mean (SD) unless otherwise specified.

Variables	Missed 1 or More MTX Dose(s), n = 45	Took all MTX Doses, n = 183	p
Age, yrs	51.96 (11.70)	53.49 (12.61)	0.46
Female, n (%)	38 (84.4)	146 (79.8)	0.47
CDAI	20.05 (15.92)	16.82 (14.39)	0.21
mHAQ	0.47 (0.50)	0.40 (0.47)	0.64
PGA, 0–100	34.71 (26.31)	27.36 (23.35)	0.08
PtGA, 0–100	45.53 (29.94)	36.81 (25.86)	0.06
Patient pain, 0–100	43.82 (31.60)	38.01 (27.06)	0.29
Disease duration, yrs	9.05 (8.85)	6.88 (8.23)	0.22
Glucocorticoid use, n (%)	15 (33.3)	44 (24.0)	0.20
Biologics, n (%)	41 (91.1)	173 (94.5)	0.39
MTX use, n (%)			0.56
Oral	19 (73.1)	143 (78.1)
SQ	7 (26.9)	40 (21.9)

RA: rheumatoid arthritis; MTX: methotrexate; CDAI: Clinical Disease Activity Index; mHAQ: modified Health Assessment Questionnaire; PGA: physician’s global assessment; PtGA: patient’s global assessment; SQ: subcutaneous.

View popup

APPENDIX 1.

Characteristics of patients with RA treated with MTX by response versus nonresponse to the survey, and those not treated with MTX by response versus nonresponse to the survey. Values are mean (SD) unless otherwise specified.

Characteristics	Treated with MTX, Responded to Survey	Treated with MTX, Not Responded to Survey	p	Not Treated with MTX, Responded to Survey	Not Treated with MTX, Not Responded to Survey	p
n	228	284		202	270
Age, yrs	53.18 (12.42)	56.62 (12.43)	0.004	53.61 (12.51)	55.02 (13.15)	0.31
Female, n (%)	184 (80.7)	213 (76.6)	0.26	163 (80.7)	225 (86.2)	0.11
CDAI	17.46 (14.72)	16.59 (13.68)	0.67	17.28 (14.38)	17.90 (13.75)	0.52
mHAQ	0.42 (0.47)	0.43 (0.45)	0.59	0.46 (0.48)	0.48 (0.48)	0.60
PGA, 0–100	28.81 (24.08)	25.99 (21.93)	0.27	27.45 (22.23)	29.12 (23.08)	0.43
PtGA, 0–100	38.53 (26.87)	40.36 (27.95)	0.52	40.52 (27.37)	43.26 (27.14)	0.32
Patient pain, 0–100	39.15 (28.03)	43.72 (29.67)	0.10	43.53 (30.07)	46.32 (29.19)	0.36
Disease duration, yrs	7.31 (8.38)	9.14 (8.82)	0.0007	9.59 (8.44)	10.04 (9.27)	0.78
Glucocorticoid use, n (%)	59 (25.9)	76 (26.8)	0.82	56 (27.7)	63 (23.3)	0.27
Biologic use, n (%)	214 (93.9)	229 (80.6)	< 0.0001	167 (82.7)	201 (74.4)	0.03

RA: rheumatoid arthritis; MTX: methotrexate; CDAI: Clinical Disease Activity Index; mHAQ: modified Health Assessment Questionnaire; PGA: physician’s global assessment; PtGA: patient’s global assessment.